Quadrature Capital Ltd Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Quadrature Capital Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 89.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,887 shares of the biopharmaceutical company’s stock after selling 16,624 shares during the period. Quadrature Capital Ltd’s holdings in Alnylam Pharmaceuticals were worth $615,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Alnylam Pharmaceuticals by 203.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock worth $76,195,000 after acquiring an additional 189,128 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after acquiring an additional 185,783 shares during the last quarter. SCS Capital Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $46,194,000. Finally, Orbis Allan Gray Ltd raised its position in shares of Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock valued at $441,462,000 after purchasing an additional 162,121 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the topic of several research analyst reports. Citigroup boosted their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. BMO Capital Markets raised their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Jefferies Financial Group dropped their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research note on Thursday, October 30th. Finally, Evercore ISI increased their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a report on Thursday, September 11th. Twenty-three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $482.17.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $454.32 on Tuesday. The business’s 50-day moving average is $455.72 and its two-hundred day moving average is $398.86. The company has a market capitalization of $60.02 billion, a P/E ratio of -183.94 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,517,119.43. This trade represents a 13.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 78,328 shares of company stock valued at $35,705,793. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.